Epigral Limited (EPIGRAL) Financial Results — Revenue ₹736 Cr

1 Financial Results 🔴 High Importance Neutral 📄 PDF

Revenue: ₹736 CrNet Profit: ₹82

📢 Key Event
Epigral reports record Q4FY26 revenue of ₹736 crore and proposes ₹5 final dividend

🔄 What Changed
Revenue grew 22% QoQ to ₹736 crore; EBITDA margin rose to 23% from 17%; PAT increased 109% QoQ to ₹82 crore; FY2026 revenue fell 1% to ₹2,542 crore; Net debt/EBITDA rose to 0.9x from 0.7x

🔮 What's Next
Expect FY27 growth momentum to continue subject to global macro conditions

💡 Investor Takeaway
Strong quarterly recovery and dividend proposal offset FY2026 revenue decline and rising leverage

Epigral Limited reported record Q4FY26 revenue of ₹736 crore, up 17% YoY and 22% QoQ, with PAT at ₹82 crore. The board proposed a final dividend of ₹5 per share. EBITDA margin improved to 23% from 17% sequentially, driven by higher volumes and utilization. FY2026 revenue declined 1% to ₹2,542 crore due to lower volumes and input cost pressures, though ROCE stood at 16%. Capex of ₹394 crore advanced projects including CPVC and Epichlorohydrin capacity expansion.

2 Financial Results 🔴 High Importance ✨ Positive 📄 PDF

📢 Key Event
Epigral reported record Q4 FY26 revenue of ₹736 crore, up 22% QoQ, with PAT rising 109% to ₹82 crore.

🔄 What Changed
Revenue grew 22% QoQ to ₹736 crore; EBITDA rose 64% to ₹169 crore; PAT increased 109% to ₹82 crore; FY26 revenue declined 1% YoY to ₹2,542 crore; Net debt/EBITDA improved to 0.9x.

🔮 What's Next
Capex projects for CPVC and Epichlorohydrin capacity expansion to be completed by H1 FY27; EBITDA margin expected to stabilize at 23%; dividend proposed at ₹5 per share.

💡 Investor Takeaway
The company delivered strong quarterly profitability with record revenue and margins, while advancing key expansion projects to drive future growth.

Epigral reported record Q4 FY26 revenue of ₹736 crore, up 22% QoQ, driven by 15% volume growth and improved realization, with EBITDA rising 64% to ₹169 crore and PAT surging 109% to ₹82 crore. FY26 revenue reached ₹2,542 crore despite a 1% YoY decline due to lower volumes, while EBITDA fell to ₹567 crore and PAT was ₹333 crore after a deferred tax benefit of ₹81 crore. The company proposed a final dividend of ₹5 per share and outlined significant capex plans for CPVC and Epichlorohydrin capacity expansion, targeting completion by H1 FY27.

📊 Stock Analysis — EPIGRAL ✨ Ask AI About This